Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?
In this era of new pneumococcal conjugate vaccines (PCV), we described and compared surveillance of invasive pneumococcal disease (IPD) and PCV policies in 30 European countries to provide guidance for Europe-wide surveillance. We confirmed the heterogeneity of surveillance systems and case definitions across countries but identified elements common to all countries, such as the availability of serotyping and the surveillance of pneumococcal meningitis. PCV impact was monitored in 11/15 countries using it. We propose steps for the monitoring of incidence rates and serotype distribution at EU level, to assess the need to introduce PCV and monitor its impact once introduced.
Hanquet
Germaine
G
Scientific Institute of Public Health, Brussels, Belgium. germaine@skynet.be
Perrocheau
Anne
A
Kissling
Esther
E
Bruhl
Daniel Levy
DL
Tarragó
David
D
Stuart
James
J
Stefanoff
Pawel
P
Heuberger
Sigrid
S
Kriz
Paula
P
Vergison
Anne
A
de Greeff
Sabine C
SC
Amato-Gauci
Andrew
A
Celentano
Lucia Pastore
LP
D018563:Disease Notification; D005060:Europe / Q000453:epidemiology; D006801:Humans; D017589:Immunization Programs; D015994:Incidence; D008586:Meningitis, Pneumococcal / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000453:epidemiology*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D011159:Population Surveillance / Q000379:methods*; D012703:Serotyping; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate